Breast cancer incidence rates in U.S. women re no longer declining

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 5, 2011, Pages 733-739

  DeSantis, Carol ^a   Howlader, Nadia ^b   Cronin, Kathleen A ^b   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER REGISTRY; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HEALTH SURVEY; HISPANIC; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; TUMOR VOLUME; UNITED STATES; WOMEN'S HEALTH;

ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INCIDENCE; MIDDLE AGED; SURVIVAL RATE; UNITED STATES;

EID: 79955759845     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0061     Document Type: Article

References (24)

1. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4.
2. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
4. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53. (Pubitemid 38040534)
5. Altekruse SF, Kosary CL, Kraphco M, Neyman N, Aminou R, Waldron E, et al. SEER Cancer Statistics Review, 1975-2007. Volume 1. Bethesda, MD: National Cancer Institute 2010.
6. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975- 2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
7. Cronin KA, Ravdin PM, Edwards BK. Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat 2009;117:223-4.
8. Krieger N, Chen JT, Waterman PD. Decline in U.S. breast cancer rates after the Women's Health Initiative: socioeconomic and racial/ethnic differentials. Am J Public Health 2010;100(Suppl 1):S132-9.
9. Surveillance, Epidemiology, and End Results (SEER) Program (www. seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Research Data, Nov 2009 Sub (1992-2007) 〈Katrina/Rita Population Adjustment〉 - Linked To County Attributes - Total U.S., 1969-2007 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission.
10. Raghunathan TE, Lepkowski JM, van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodol 2001;27:85-95.
11. Joinpoint Regression Program, Version 3.4.3. April. 2010; Statistical Research and Applications Branch, National Cancer Institute.
12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
13. De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst 2010;102:1489-95.
14. Glass AG, Lacey JV, Jr., Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-61.
15. Ereman RR, Prebil LA, Mockus M, Koblick K, Orenstein F, Benz C, et al. Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. BMC Public Health 2010;10:228.
16. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366-76. (Pubitemid 41487804)
17. Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008;168:370-7. (Pubitemid 351347128)
18. Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer 2010 [Epub ahead of print] DOI: 10.1002/cncr.25679.
19. Byers T, Trujillo S, Hines L. Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2008;100:596.
20. Pfeiffer RM, Mitani A, Matsuno RK, Anderson WF. Racial differences in breast cancer trends in the United States (2000-2004). J Natl Cancer Inst 2008;100:751-2.
21. Marshall SF, Clarke CA, Deapen D, Henderson K, Largent J, Neuhausen SL, et al. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 2010;12:R4.
22. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134:e48-72.
23. Hausauer AK, Keegan TH, Chang ET, Clarke CA. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African- American women in the U.S.: changes by tumor subtype. Breast Cancer Res 2007;9:R90.
24. Agurs-Collins T, Dunn BK, Browne D, Johnson KA, Lubet R. Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. Semin Oncol 2010;37:384-401.